Cohort 2 In Cohort 2, no significant hematologic parameter alterations were observed in the leukocyte counts for either group
Dealers may also encounter more structured risk-sharing arrangements, including recourse provisions or first-payment default terms, as lenders balance opportunity with portfolio management
However, it is still being studied and is not currently approved for routine medical use
When added to tirzepatide, the additional weight loss is modest but the metabolic benefits (improved insulin sensitivity, enhanced GLP-1 signaling, reduced hepatic fat) contribute to better overall outcomes and potentially more sustainable long-term weight maintenance
Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan Jr HG (1993)